Blood anesthesia for cardiopulmonary bypass

Area of Science:

• Biomedical Engineering
• Cardiovascular Surgery
• Hematology

Background:

• Cardiopulmonary bypass (CPB) is associated with significant bleeding, thrombotic complications, fluid retention, and temporary organ dysfunction.
• These morbidities stem from the activation of blood proteins and cells upon contact with non-endothelial surfaces in the surgical wound and extracorporeal circuit.
• Heparin, the standard anticoagulant, is insufficient to prevent the activation of multiple plasma protein systems and blood cells, leading to the release of numerous vasoactive substances and microemboli.

Purpose of the Study:

• To explore the concept of "blood anesthesia" as a strategy to mitigate CPB-induced complications.
• To investigate the potential of reversible inhibitors to temporarily block key blood reactions during CPB.
• To assess the feasibility of suppressing CPB-induced vasoactive substance and microemboli production.

Main Methods:

• The study proposes the use of reversible inhibitors targeting key blood reactions.
• Focuses on blocking initial blood-surface interactions to prevent downstream activation.
• Reviews the development and testing of reversible inhibitors for various blood components.

Main Results:

• Blocking initial blood reactions is hypothesized to suppress the production of vasoactive substances and microemboli.
• This approach aims to conserve blood elements normally consumed during CPB.
• Reversible platelet inhibitors are in clinical trials, with other inhibitors under rapid development.

Conclusions:

• The "blood anesthesia" concept, utilizing reversible inhibitors, holds promise for reducing CPB-related morbidity.
• Suppression of blood activation can preserve blood components for post-CPB availability.
• Ongoing research into reversible inhibitors is crucial for advancing CPB safety and efficacy.